Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD.
Rodriguez R, Nademanee A, Palmer JM, Parker P, Nakamura R, Snyder D, Pullarkat V, Zain J, Smith E, Sahebi F, Patane K, Senitzer D, Chang K, Forman SJ. Rodriguez R, et al. Among authors: parker p. Bone Marrow Transplant. 2010 Jan;45(1):205-7. doi: 10.1038/bmt.2009.112. Epub 2009 Jun 8. Bone Marrow Transplant. 2010. PMID: 19503110 Clinical Trial. No abstract available.
A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant.
Khaled SK, Palmer J, Stiller T, Senitzer D, Maegawa R, Rodriguez R, Parker PM, Nademanee A, Cai JL, Snyder DS, Karanes C, Osorio E, Thomas SH, Forman SJ, Nakamura R. Khaled SK, et al. Among authors: parker pm. Bone Marrow Transplant. 2013 Feb;48(2):278-83. doi: 10.1038/bmt.2012.175. Epub 2012 Sep 24. Bone Marrow Transplant. 2013. PMID: 23000644 Free PMC article. Clinical Trial.
Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
Rodriguez R, Parker P, Nademanee A, Smith D, O'Donnell MR, Stein A, Snyder DS, Fung HC, Krishnan AY, Popplewell L, Cohen S, Somlo G, Angelopoulou M, Al-Kadhimi Z, Falk PM, Spielberger R, Kogut N, Sahebi F, Senitzer D, Slovak M, Schriber J, Forman SJ. Rodriguez R, et al. Among authors: parker p. Bone Marrow Transplant. 2004 Jun;33(11):1123-9. doi: 10.1038/sj.bmt.1704493. Bone Marrow Transplant. 2004. PMID: 15064696 Clinical Trial.
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.
Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R, Cohen S, Falk P, Fung H, Kirschbaum M, Krishnan A, Kogut N, Molina A, Nakamura R, O'Donnell M, Popplewell L, Pullarkat V, Rosenthal J, Sahebi F, Smith E, Snyder D, Somlo G, Spielberger R, Stein A, Sweetman R, Zain J, Forman S. Lopez F, et al. Among authors: parker p. Biol Blood Marrow Transplant. 2005 Apr;11(4):307-13. doi: 10.1016/j.bbmt.2005.01.011. Biol Blood Marrow Transplant. 2005. PMID: 15812396 Free article.
Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates.
Nakamura R, Auayporn N, Smith DD, Palmer J, Sun JY, Schriber J, Pullarkat V, Parker P, Rodriguez R, Stein A, Rosenthal J, Wang S, Karanas C, Gaal K, Senitzer D, Forman SJ. Nakamura R, et al. Among authors: parker p. Biol Blood Marrow Transplant. 2008 Apr;14(4):449-57. doi: 10.1016/j.bbmt.2008.02.005. Biol Blood Marrow Transplant. 2008. PMID: 18342788 Free PMC article.
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O'Donnell M, Krishnan AY, Senitzer D, Forman SJ. Rodriguez R, et al. Among authors: parker p. Blood. 2010 Feb 4;115(5):1098-105. doi: 10.1182/blood-2009-03-207563. Epub 2009 Nov 19. Blood. 2010. PMID: 19965688 Free PMC article. Clinical Trial.
Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch.
Al Malki MM, Gendzekhadze K, Yang D, Mokhtari S, Parker P, Karanes C, Palmer J, Snyder D, Forman SJ, Nademanee A, Nakamura R. Al Malki MM, et al. Among authors: parker p. Transplantation. 2020 May;104(5):1070-1080. doi: 10.1097/TP.0000000000002932. Transplantation. 2020. PMID: 31449184 Free PMC article.
Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation.
Malki MMA, Gendzekhadze K, Stiller T, Mokhtari S, Karanes C, Parker P, Snyder D, Forman SJ, Nakamura R, Nademanee A. Malki MMA, et al. Among authors: parker p. Bone Marrow Transplant. 2020 Feb;55(2):409-418. doi: 10.1038/s41409-019-0694-y. Epub 2019 Sep 24. Bone Marrow Transplant. 2020. PMID: 31551519 Free PMC article.
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.
Nakamura R, Palmer JM, O'Donnell MR, Stiller T, Thomas SH, Chao J, Alvarnas J, Parker PM, Pullarkat V, Maegawa R, Stein AS, Snyder DS, Bhatia R, Chang K, Wang S, Cai JL, Senitzer D, Forman SJ. Nakamura R, et al. Leuk Res. 2012 Sep;36(9):1152-6. doi: 10.1016/j.leukres.2012.04.022. Epub 2012 Jun 5. Leuk Res. 2012. PMID: 22677229 Free PMC article.
1,371 results